UTHR vs. BMRN, IONS, ALNY, MDGL, ALKS, RDY, SRPT, VTRS, CTLT, and ROIV
Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include BioMarin Pharmaceutical (BMRN), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Viatris (VTRS), Catalent (CTLT), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical preparations" industry.
BioMarin Pharmaceutical (NASDAQ:BMRN) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability.
BioMarin Pharmaceutical received 966 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 74.70% of users gave BioMarin Pharmaceutical an outperform vote while only 61.71% of users gave United Therapeutics an outperform vote.
BioMarin Pharmaceutical currently has a consensus target price of $106.11, suggesting a potential upside of 36.80%. United Therapeutics has a consensus target price of $308.78, suggesting a potential upside of 12.59%. Given United Therapeutics' higher possible upside, equities research analysts plainly believe BioMarin Pharmaceutical is more favorable than United Therapeutics.
98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 1.9% of BioMarin Pharmaceutical shares are owned by company insiders. Comparatively, 12.5% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
United Therapeutics has lower revenue, but higher earnings than BioMarin Pharmaceutical. United Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
United Therapeutics has a net margin of 42.05% compared to United Therapeutics' net margin of 8.31%. BioMarin Pharmaceutical's return on equity of 18.72% beat United Therapeutics' return on equity.
In the previous week, BioMarin Pharmaceutical had 18 more articles in the media than United Therapeutics. MarketBeat recorded 34 mentions for BioMarin Pharmaceutical and 16 mentions for United Therapeutics. BioMarin Pharmaceutical's average media sentiment score of 0.86 beat United Therapeutics' score of 0.24 indicating that United Therapeutics is being referred to more favorably in the news media.
BioMarin Pharmaceutical has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.
Summary
BioMarin Pharmaceutical and United Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get United Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
United Therapeutics Competitors List
Related Companies and Tools
